Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PD-1 Inhibitor and Sorafenib for Advanced Liver Cancer
NCT04163237Phase 3Unknown
- Sponsor
- Guangxi Medical University
- Start
- Dec 2019
- Primary completion
- Oct 2020
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial in hepatocellular carcinoma (HCC) (2 arms), sponsored by Guangxi Medical University. Primary endpoint: Disease-free Survival at 1 year. Status: unknown.
02
Conditions
hepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on NCT04163237.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04163237.